Diamonds and Dogs
Sherwin Williams (SHW) is painting the town red. Sherwin Williams is jumping 8% just under the all-time high following better than expected earnings. The company reported 13 cents better than expected as revenues rose 6.8% year over year to $2.78 billion. Guidance didn't look great, but shareholders liked it. The company is in the midst of acquiring rival, Valspar to become a paint juggernaut.
Drug stocks still in the dog house. Bristol-Myers (BMY) is down 4% sinking to a four year lower after disappointing earnings and lowered guidance. Revenues rose an impressive 22.3% year over year, but investors are focused on lowered guidance for the first quarter as worldwide revenue will only increase by low-single digits instead of the previous forecast of high-teens growth rate. Gross margins will also be lower. The rest of drug sector isn't doing much better. Biotech, Celgene is down a percent following earnings as well.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.